WASHINGTON — Tranexamic acid administered intravenously before and after noncardiac surgery lowered the risk for life-threatening, major and critical organ bleeding compared with placebo, according to results of the POISE-3 trial.
Although 1 g IV bolus tranexamic acid cut bleeding risk at 30 days, noninferiority was not established for the composite vascular outcome compared with placebo, researchers reported at the American College of Cardiology Scientific Session.
“The majority of patients undergoing noncardiac surgery do not receive tranexamic acid. There is an annual global